Advanced in Virilizing Ovarian Tumor

Dr. Rachel E. Lerner

Park Nicollet Clinic
St Louis Park, MN
Advanced
in Virilizing Ovarian Tumor
Specialties:Hematology Oncology | Hematology | Oncology
Accepting New Patients
Offers Telehealth
OverviewInsuranceLocationsClinical Research

Overview

Rachel Lerner is a Hematologist Oncology specialist and a Hematologist in St Louis Park, Minnesota. Dr. Lerner and is rated as an Advanced provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Paget Disease of the Breast, Familial Colorectal Cancer, Familial Pancreatic Cancer, and Ovarian Carcinosarcoma. Dr. Lerner is currently accepting new patients.

Her clinical research consists of co-authoring 6 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in MN
Hospital Affiliations
Park Nicollet Methodist Hospital
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Medica
  •  Humana

Locations

PARK NICOLLET CLINIC
3931 Louisiana Ave S, St Louis Park, MN 55426
952-993-1990

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Procedure, Drug, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Drug
Study Drugs: Palbociclib, Trastuzumab, Pertuzumab, Letrozole, Anastrozole, Exemestane, Fulvestrant
Study Phase: Phase 3
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
Enrollment Status: Active_not_recruiting
Publish Date: December 10, 2024
Intervention Type: Other, Drug, Biological
Study Drugs: Bevacizumab, Carboplatin, Docetaxel, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)
Enrollment Status: Active_not_recruiting
Publish Date: November 14, 2024
Intervention Type: Drug, Other
Study Drug: Ribociclib
Study Phase: Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2024
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Enrollment Status: Completed
Publish Date: September 01, 2022
Intervention Type: Other
Stool Collection Sub-Study of Exact Sciences Protocol 2018-01: Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Stool Collection Sub-Study of Exact Sciences Protocol 2018-01: Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Enrollment Status: Completed
Publish Date: June 06, 2022
Intervention Type: Other
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)
Enrollment Status: Unknown
Publish Date: May 24, 2022
Intervention Type: Other, Radiation, Drug
Study Drug: Cisplatin
Study Phase: Phase 3
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Enrollment Status: Unknown
Publish Date: September 30, 2021
Intervention Type: Other, Drug
Study Drugs: Carboplatin, Metformin hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
View 8 Less Clinical Trials
Similar Doctors
Expertise in
27
conditions
Dr. Amy B. Spomer
Hematology Oncology | Oncology | Hematology
Expertise in
27
conditions
Dr. Amy B. Spomer
Hematology Oncology | Oncology | Hematology

Park Nicollet Clinic

3800 Park Nicollet Blvd, Mailstop 61n01i, 
St Louis Park, MN 
 (0.9 mi)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Amy Spomer is a Hematologist Oncology specialist and an Oncologist in St Louis Park, Minnesota. Dr. Spomer and is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Paget Disease of the Breast, Virilizing Ovarian Tumor, Ovarian Carcinosarcoma, and Testicular Yolk Sac Tumor. Dr. Spomer is currently accepting new patients.

Expertise in
50
conditions
Dr. Dahlia H. Elkadi
Hematology Oncology | Hematology | Oncology
Expertise in
50
conditions
Dr. Dahlia H. Elkadi
Hematology Oncology | Hematology | Oncology

St Cloud Hospital

1406 6th Ave N, 
Saint Cloud, MN 
 (59.5 mi)
320-251-2700
Experience:
36+ years
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients
Offers Telehealth

Dahlia Elkadi is a Hematologist Oncology specialist and a Hematologist in Saint Cloud, Minnesota. Dr. Elkadi has been practicing medicine for over 36 years and is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Virilizing Ovarian Tumor, Ovarian Carcinosarcoma, Testicular Yolk Sac Tumor, Bone Marrow Aspiration, and Endoscopy. Dr. Elkadi is currently accepting new patients.

Expertise in
30
conditions
Dr. Steven R. Rousey
Hematology Oncology | Hematology | Oncology
Expertise in
30
conditions
Dr. Steven R. Rousey
Hematology Oncology | Hematology | Oncology

Glencoe Regional Health Services

1805 Hennepin Ave N, 
Glencoe, MN 
 (40.1 mi)
320-864-3121
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Steven Rousey is a Hematologist Oncology specialist and a Hematologist in Glencoe, Minnesota. Dr. Rousey and is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Myeloproliferative Neoplasms (MPN), Chronic Familial Neutropenia, Colorectal Cancer, and Chronic Lymphocytic Leukemia (CLL). Dr. Rousey is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile